ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,538Medicare Part D Prescriptions Filled, Including Refills

Rank: 20 out of 229

$525K Total Retail Price of All Prescriptions

Rank: 41 out of 229

801 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
27% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Mexico
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 801 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

12% of this provider’s 801 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

1% of this provider’s 10,407 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $59 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Mexico
LISINOPRIL 898 791 1 2
LEVOTHYROXINE SODIUM 646 596 2 1
AMLODIPINE BESYLATE 584 553 3 5
LOSARTAN POTASSIUM 461 447 4 12
PRAVASTATIN SODIUM 446 433 5 25
LOVASTATIN 388 345 6 11
HYDROCHLOROTHIAZIDE 379 362 7 9
HYDROCODONE-ACETAMINOPHEN 331 297 S3 8 7
OMEPRAZOLE 316 294 9 4
METFORMIN HCL 266 240 10 6
ZOLPIDEM TARTRATE 200 193 11 20
METOPROLOL TARTRATE 196 180 12 13
SIMVASTATIN 189 174 13 3
FUROSEMIDE 179 170 14 8
CITALOPRAM HBR 156 135 15 21
TAMSULOSIN HCL 144 141 16 24
ALENDRONATE SODIUM 140 133 17 14
LABETALOL HCL 131 131 18 143
TERAZOSIN HCL 124 124 19 74
GABAPENTIN 123 120 20 10
OXYCODONE HCL 119 97 S2 21 37
PANTOPRAZOLE SODIUM 114 107 22 33
ATENOLOL 112 100 23 19
RANITIDINE HCL 111 106 24 32
FLUTICASONE PROPIONATE 107 82 25 23
FINASTERIDE 106 106 26 55
WARFARIN SODIUM 102 101 27 17
OXYCODONE-ACETAMINOPHEN 100 84 S2 28 43
POTASSIUM CHLORIDE 98 91 29 18
PREDNISONE 83 83 30 35
DONEPEZIL HCL 81 81 31 29
TRAMADOL HCL 77 69 32 26
TRAZODONE HCL 72 57 33 34
GEMFIBROZIL 70 59 34 62
DIOVAN 69 57 35 42
FENOFIBRATE 66 65 36 68
MIRTAZAPINE 64 64 37 52
HYDRALAZINE HCL 62 56 38 78
CLONIDINE HCL 62 54 38 69
LANTUS 60 45 40 40
ALLOPURINOL 60 53 40 27
NAMENDA 58 58 42 39
ATORVASTATIN CALCIUM 58 52 42 15
METOPROLOL SUCCINATE 58 56 42 16
SERTRALINE HCL 56 52 45 22
CIPROFLOXACIN HCL 53 51 46 58
OXYCODONE HCL-ACETAMINOPHEN 53 33 S2 46 73
FLOVENT HFA 52 39 48 115
JANUVIA 50 41 49 59
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 17, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.